How is Alnylam Pharmaceuticals (ALNY) doing?
Alnylam Pharmaceuticals is a company in the biotechnology industry, based in Cambridge, MA, worth $31.1B. Here is how its shares and business compare with the rest of the market, and where it shows up on our dashboards.
Updated Oct 9, 2026
Weak
Alnylam Pharmaceuticals shares are down 48% over the past year, 55 points behind the S&P 500. Its type is Coiled Spring. Among large US stocks and funds it ranks in the 2nd percentile on market beat, the 69th on staying power and the 99th on business growth. It appears on 10 of our dashboards, including 3rd on “Which businesses are getting better?” and 4th on “Which companies are growing fastest?”.
Compare with VRTX · REGN · BMRN · RARE · IONS · SRPT · BIIB · INCY · INSM
Financials, earnings and news on Stox ›The past year
Price against the S&P 500, each set to $100 a year ago. Score is its weekly rank against the market. Select a tile for that score month by month.
What kind of stock is it?
Its type on Stox Atlas, from its four scores: beating or lagging the market, a steady or erratic rank, a growing or slowing business, and whether buyers or sellers lead.
Coiled Spring
Behind the market but holding its rank, with a growing business and buyers stepping in.
Coiled Spring this month; Show-Me Grower before that.
Also Coiled Spring (60 in all): INSP · IDXX · BSX · PODD · AFRM · RRC
How is it doing against its group?
Its group is Health care, 86 large US stocks and funds whose prices tend to move together. Tools, biotech and large-cap pharma — defensive growth.
Alnylam Pharmaceuticals is −48% over the past year, against +22% for the rest of the group and +16% for the S&P 500. It ranks 83rd of 86 in Health care.
How much does it move?
Its typical daily move, against its own past year, the market and other large stocks. Swings describe risk, not direction.
About usual Alnylam Pharmaceuticals typically moves 4.3% in a day, about usual for it, and it swings more than 77% of large US stocks.
ALNY on our dashboards
Every question where Alnylam Pharmaceuticals appears, in the order of the home page, with its reading and place in that table. Select a question to open it with ALNY highlighted. Select a column to sort.
| Question | Reading | Place | Details |
|---|---|---|---|
| What are this year’s biggest winners and losers? What’s leading | 3Bottom | 48 of 60 | This year −41% · vs S&P −56 pts · Past month −6% |
| Who is joining or leaving the S&P 500? Events | –Candidate | 10 of 66 | Market value $31.1B · 1Y −48% |
| Which stocks keep losing? Leading stocks | 9733 of 52 wks | 14 of 60 | vs S&P, 1Y −64 pts |
| Which companies are growing fastest? Business quality | 99Fast | 4 of 60 | Revenue, 1Y +95% · Change +90 pts |
| Who is outgrowing its rivals? Business quality | 99Outgrowing | 4 of 60 | Revenue, 1Y +95% · Rivals +10% · Lead +85 pts |
| Whose profit margins are widening? Business quality | 99Widening | 5 of 60 | Change, 1Y +28.1 pts · Operating margin 21% · Gross margin 80% |
| Which businesses are getting better? Business quality | 99Improving | 3 of 60 | Revenue growth +83% · Operating margin 18% |
| Which companies invest the most in research? Business quality | 95Heavy | 11 of 60 | R&D / revenue 31.4% · R&D a year $1.5B · R&D, 1Y +30% |
| Which companies pay the most in stock? Dividends and buybacks | 92Heavy | 31 of 60 | % of revenue 7.0% · A year $336.6M · % of cash flow 62% |
| What are insiders buying? Who’s buying and selling | –Selling | 35 of 60 | Sold $399K · Who Evp, CLO And Secretary |
Go deeper on Stox
ALNY’s full profile: financial statements, earnings and analysts’ estimates, valuation against its sector, recent news with a summary, and its scores in detail.
How to read this page
How it’s measured. Scores from Stox rank the stock against about 1,200 S&P 500, Nasdaq-100 and Russell 1000 stocks and popular funds, where 100 is best; market beat and staying power use prices, business growth uses revenue, margins and cash flow. Readings on other dashboards come from this site’s pages.
Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and co-movement groups from Stox.
Scores are percentiles: 80 means the stock ranks above 80% of the others on that measure. They describe the recent past and are not advice or a forecast.
Its type follows Stox Atlas: each of the four scores is split at 50. “Steady” means its rank has held, high or low, so it says nothing on its own about direction.
Its group is the cluster of large US stocks whose prices have moved together over five years, with the market’s own moves taken out. The typical daily move is the average true range over 14 days, a measure of how far the price travels in a day including overnight gaps.
For financial statements, earnings and news, see ALNY’s full profile on Stox.
This page is information, not investment advice. About our data and methods ›